Geoffrey von Maltzahn, who served as Tessera’s founding CEO, will transition to Board Chair and continue to stay closely involved in the company’s efforts to transform genetic medicine with treatments for diseases and vulnerabilities through its GENE WRITING platforms. Tessera’s GENE WRITING technology consists of multiple platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. “Mike’s R&D expertise and years of experience leading innovative strategies for notable biopharmaceutical companies will help drive Tessera’s growth and the translation of its pioneering technology.”Īfeyan added, “Under Geoff von Maltzahn’s leadership as founding CEO of Tessera, the company has created strong platform foundations and is poised for the next phase of growth as Geoff transitions into the Board Chair role.” “Mike will play a critical role at Flagship as CEO-Partner and, through that position, take on the role as CEO of Tessera, a company revolutionizing genetic medicine,” said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Tessera Co-Founder and Board member. Prior to Amgen, he was Senior Director at Merck & Co., Inc., responsible for leading research in multiple areas, including clinical genomics, molecular profiling, and experimental medicine. Severino held several senior leadership roles at Amgen, leading to his appointment as Senior Vice President and Corporate Chief Medical Officer where he oversaw the company's global clinical research efforts. In his roles at AbbVie as Executive Vice President of Research and Development, Chief Scientific Officer and most recently Vice Chairman and President, he led efforts to build a strong pipeline and advance promising science for patients in the areas of hematologic oncology, immunology, and neuroscience. Severino brings more than two decades of biopharmaceutical leadership to Tessera, having led the strategy behind research, development, registration, and commercialization of more than a dozen FDA-approved therapies. Severino, who was previously Vice Chairman and President of AbbVie, also serves as a Flagship Pioneering CEO-Partner.ĭr.

CAMBRIDGE, Mass.Flagship Pioneering, the bioplatform innovation company, and Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced that Michael Severino, M.D., has joined Tessera as Chief Executive Officer.

Tessera therapeutics stock